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SUMMARY
INTRODUCTION: In acute myocardial infarction (AMI), each 18 mg/dl (1 mmol/L) increment is associated with a 3% increase in mortal-
ity rates. All strategies applied for reducing blood glucose to this date, however, have not presented encouraging results.
METHODOLOGY: We searched the Medline (PubMed) and Cochrane Library databases for randomized clinical trials (RCTs) from 1995 
to 2017 that used the intensive strategy or GIK therapy for blood glucose control during the acute stage of the AMI. We included eight 
studies. In order to identify the effects of GIK or insulin therapy, we calculated a overall risk ratio (RR) with meta-analysis of fixed and 
random effects models. A two-tail p-value of < 0.05 was considered statistically significant.
RESULTS: A total of 28,151 patients were included: 1,379 intensively treated with insulin, 13,031 in GIK group, and 13,741 in the control 
group. The total mortality was 10.5% (n=2,961) and the RR of 1.03 [95%CI 0.96–1.10]; I2 = 31%; p = 0.41 for the combined intensive 
insulin plus GIK groups in comparison with the control group. In meta-regression analyses, intense reductions in blood glucose (> 36 
mg/dL) in relation to the estimated average blood glucose (estimated by HbA1c) were associated with higher mortality, whereas lower 
reductions in blood glucose (< 36 mg/dL) were not associated with mortality. The lowering of blood glucose in the acute phase of MI 
compared with the average blood glucose was more effective around 18 mg/dL.
CONCLUSION: This meta-analysis suggests that there may be a tenuous line between the effectiveness and safety of reducing blood 
glucose in the acute phase of MI. The targets must not exceed a reduction greater than 36 mg/dL in relation to estimated average 
blood glucose. 
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INTRODUCTION
Stress hyperglycemia is a powerful prognostic 
marker for acute myocardial infarction (AMI)1,2. It 
represents not only a consequence of inflammatory 
activation, adrenergic and endocrine but also con-
tributes to the continuation of these phenomena. In 
AMI patients, each 18 mg/dl (1 mmol/L) increment is 
associated with a 3% increase in mortality due to all 
causes1. In a different study, each increment of capil-
lary blood glucose over 140 mg/dl was translated as 
a directly proportional increase in the mortality of 
these patients over five years2.
Overall, however, all strategies applied for re-
ducing blood glucose to this date have not present-
ed encouraging results. As the first strategy for the 
intensive control of blood glucose, the Digami-13 pre-
sented an aggressive reduction in the blood glucose 
of diabetic patients with AMI was associated with a 
decrease in mortality. However, these findings could 
not be reproduced by subsequent studies – both Di-
gami-24 and HI-55 failed to demonstrate the benefits 
of using the intensive treatment for blood glucose 
during an acute coronary event. Randomized studies 
with the same purpose of comparing a more rigor-
ous treatment for stress hyperglycemia with more 
conservative methods, in the context of other critical 
conditions, also failed, like the multicenter Nice-Sug-
ar6. This study suggested a 14% increase in patient 
mortality with the intensive control of hyperglyce-
mia, overall, due to an increase in the risk of hypo-
glycemia.
The concept of metabolic modulation in the acute 
stage of AMI with the purpose of promoting electrical 
stability in the myocardium after an ischemic event 
started in 1960 with the glucose-insulin-potassium 
therapy (GIK)7. However, there is an extremely tenu-
ous balance between the plasma glucose and insulin 
resistance in the ischemic myocardium, in which, 
on the one hand, there is a necessity for high blood 
glucose levels in order to defeat the cellular mecha-
nisms for insulin resistance and, on the other hand, 
a relative insulin deficiency in the acute stage. The 
mere provision of glucose and insulin could facilitate 
the glucose uptake by the myocardium, provided that 
in balance with the glucose consumption rate. If that 
balance is broken, the deleterious effect of hypogly-
cemia or hyperglycemia will prevail.
In studies such as Digami I and II, Gips I8 and II9, 
Create-Ecla10, and other trials, the diametrically op-
posite impacts on cardiovascular mortality due to all 
causes were not revealed. Although the proportion 
of hypoglycemia partially explains these findings, 
there is no clear explanation for such divergent re-
sults. In order to answer that question, we propose 
a meta-analysis followed by meta-regression using 
data published from trials on the intensive control of 
blood glucose in the acute stage of AMI.
METHODS
A detailed description of all the procedures is 
included in the Supplementary Data (from the Data 
Source and Research section to the Studies Included 
and Excluded). In short, the Medline (PubMed), Co-
chrane Library and ClinicalTrials.gov databases were 
searched for original articles from 1995 to 2017 in or-
der to identify all randomized clinical trials (RCTs) 
that used an intensive strategy or GIK therapy for the 
control of blood glucose levels during the acute stage 
of AMI. Original essays were considered eligible for 
the present meta-analysis if they met the following 
criteria: 1) Phase 2 or 3 RCT; 2) participants of the 
AMI acute event; 3) the participants of the treatment 
group used insulin or GIK therapy during the study. 
We excluded the studies that, despite being related 
to this subject,  did not present mortality data or a 
comparison between a more intensive strategy for 
the control of stress hyperglycemia with more con-
servative strategies, or that presented biases in the 
randomization or data analysis. Two researchers an-
alyzed the data using pre-set forms and independent-
ly assessed the precision of the analysis, resolving 
any discrepancies through a consensus after a dis-
cussion with the third researcher. The baseline data 
were obtained through weighted calculation. In order 
to identify the potential effects of GIK or insulin ther-
apy in the AMI, we calculated an overall risk ratio 
(RR) with meta-analysis of fixed and random effects 
models. Odds Ratios and risk ratios were universal-
ly identical during the data analysis. More details on 
the data analysis can be found in Annex 1 (Data Anal-
ysis and Synthesis). For the estimate of the effects of 
the resumed treatment, a two-tail p-value of < 0.05 
was considered statistically significant. We used Sta-
ta 13 to analyze the data.
RESULTS
In total, we identified over 20 studies on the con-
trol of hyperglycemia in events of acute myocardial 
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infarction, out of which nine were included in our 
study (Table 1). All other studies were not included 
in our meta-analysis because they did not present 
assessments of the polarity of more intensive or con-
servative approaches.
With that in mind, the studies analyzed were con-
ducted between the years of 1995 and 2007 and all 
were clinical trials with a multicenter and random-
ized design. The average of follow-up for all the stud-
ies was of 11.5 months; Digami-1 was the one with 
the longest patient follow-up time (40.8 months), 
while all the others (except for Digami-2, which fol-
lowed-up with the patients for 36 months) had a fol-
low-up time between one and six months. In total, 
there were 28,151 patients included; of these, 1,379 
were included in the group for intensive capillary 
blood glucose treatment, while 13,031 were in the 
group for GIK treatment, and 13,741 in the control 
group (734 in the studies that were compared with 
the intensive strategy, and 13,007 in the studies that 
assessed the use of GIK). In total, about 34.7% of pa-
tients were female, with an average age of 62.6 years.
After dividing the sample between the studies 
that sought blood glucose levels with an emphasis on 
a more intensive regimen of insulin in the acute stage 
of infarction, we had 2,113 patients in the intensive 
treatment group, and 734 in the control group, with 
39% of patients being female, with an average age 
of 66.1 years. In this subgroup, the average pre-ran-
domized blood glucose of patients was of 234.72 mg/
dl, with a 7.45% mean value for glycated hemoglobin 
(HbA1C) for these patients. After separating the pa-
tients into the intensive and conservative treatment 
groups, for the first group, the average blood glucose 
value was of 148.68 mg/dl, while on the latter it was 
of 159.48 mg/dl, with post-follow-up HbA1C values of 
7.06% and 7.1 %, respectively.
As for the studies that assessed the use of the glu-
cose-insulin-potassium therapy solution, there was a 
total of 26,038 patients, with 13,031 in the GIK group 
and 13,007 in the conservative treatment group. There 
was an average of 32.6% female patients, with an av-
erage age of 60.9 years. The average pre-randomized 
blood glucose was of 150.48 mg/dl between the sub-
TABLE 1 – DESCRIPTIVE ANALYSIS OF THE STUDIES ANALYZED






Year 1995 2005 2006 2003 2007 2005 2004 2006 1999
Design RCT RCT RCT RCT RCT RCT RCT RCT RCT
Follow-up (months) 40.8 36 6 1 6 1 6 1 6
Female (%) 62.5 33 21.6 60.1 27.6 22.4 27.9 26.4 31.4
Average pre-randomized age 
(years)
67.5 68.3 62.6 60.3 61.8 58.6 62.4 61.5 61.0
Pre-randomized DM II (%) 100 100 48.3 14.5 17.7 23.1 9.5 6.3
DM II in insulin use (%) 34.6 31.1 7.9 2.5 1.9
Heart failure (%) 21.9 23.9 8.2 13.5 1.65 7.7
Undiagnosed DM II (%) 12.5
Pre-randomized HbA1C (%) 8.1 7.26 7.0
Pre-randomized blood glucose 
(mg/dl)
279 229.1 196.2 153 160.2 162 153 124.2
Intensive treatment sample 306 947 126
Conservative treatment sample 314 306 114 464 1,374 10,107 157 445 460
GIK sample 476 1,374 10,088 155 444 494





172.8 180 145.8 145.8 133.2 135 111.6
Post-GIK blood glucose (mg/dl) 138.6 151.2 154.8 106.2






RCT – Randomized Clinical Trial; DM II – Type II Diabetes Mellitus; GIK – glucose-insulin-potassium solution; HbA1C – Glycated Hemoglobin.
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groups, with 131.4 mg/dl for patients of the conserva-
tive treatment and 137.7 mg/dl in the GIK group.
The mortality rates for all causes are described in 
Figure 1. The grouped data show that the total mortal-
ity of the studies included was of 2,961 (10.5%). When 
once again divided into subgroups, there were 330 
in the group for intensive control of capillary blood 
glucose, against 204 in the group for the conservative 
treatment (15.6% against 9.6%, respectively). Among 
the patients assessed for the GIK treatment, the total 
mortality was of 1,186 individuals (4.7%) for patients 
who used this strategy, against 1,186 patients of the 
conservative treatment (4.5%). Thus, the risk ratio for 
mortality due to all causes was of 1.03 [95% CI 0.96–
1.10]; I2 = 31%; p = 0.41). As shown in Supplementary 
Figure 1, there was no significant publication bias in 
the funnel charts and no significant bias concerning 
small studies, according to the Egger tests (p = 0.57).
Finally, with the purpose of finding possible ex-
planations for the discrepant findings between the 
trials, we conducted a series of meta-regressions 
(Supplementary Figures 2 and 3). As shown in figure 
2, we can see that abrupt and intense reductions in 
blood glucose in relation to the average estimated 
blood glucose (> 2 mmol/L or > 35 mg/dL) were asso-
ciated with a higher risk of death, while reductions 
with low intensity (around zero) were not significant-
ly associated with an increment or reduction in mor-
tality due to all causes. Contrastingly, the lowering of 
blood glucose in the acute stage compared with the 
average blood glucose was more effective around 1 
mmol/L 18 mg/dL (p = 0.008 for the tendency in the 
restricted cubic spline).
DISCUSSION
The present systematic review assessed the im-
pact of the intensive control of blood glucose levels 
in the acute stage of AMI, following different strat-
egies, over the mortality due to all causes. A raw 
analysis of the impact of intensive control suggests 
there is no difference in comparison with the usu-
al control. However, we have shown there is a fine 
limit between the magnitude of the fasting glucose 
reduction in relation with the average blood glucose 
levels before the AMI (based on the glycated hemo-
globin) and the results of the intensive blood glucose 
control approach. In this context, intense and abrupt 
reductions of blood glucose (> 2 mmol/L or > 35 mg/
dL) seem to lead to a higher risk of death, while re-
FIGURE 1
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ductions with low intensity (around zero) seem not 
to influence death risk. On the other hand, a reduc-
tion of around 1 mmol/L (or 18 mg/dL) of the blood 
glucose during the acute stage compared with the 
estimated average seems to be the most secure and 
effective strategy to reduce the risk of death due to 
all causes in the context of AMI.
Stress hyperglycemia is common in the context 
of critically ill patients6 and is not different from the 
acute stage of the acute myocardial infarction1,2,11,12. 
It is a powerful risk marker since it reflects the sys-
temic and sympathetic activity and plasma levels of 
catecholamines, cortisol, and glucagon after the isch-
emic event13. When it is present at the AMI patient’s 
admission into hospital, it is related with higher mor-
tality rates, worse outcomes in primary angioplasty 
and an increase in the number of Timi 0 flows in 
coronary angiographies, as well as a more significant 
development of heart failure and cardiogenic shock. 
The pathophysiology is still little known; however, it 
is known that the hyperglycemia is associated with 
endothelial dysfunction in the context of acute AMI15.
The cells of the vascular endothelium play an es-
sential part in cardiovascular homeostasis, secret-
ing a series of mediators that regulate the platelet 
aggregation, coagulation, and vascular tonus16. The 
term “endothelial dysfunction” refers to a condition 
in which the endothelium loses its physiological 
properties, with a tendency of promoting arteriolar 
vasodilation, fibrinolysis, and anti-aggregation. The 
mediators secreted by these cells can perform both 
vasoconstriction, through endothelin-1 and throm-
boxane A2, and vasodilation through nitric oxide and 
prostacyclin. In patients with hyperglycemia and dia-
betes, there is a deficiency in the production of nitric 
oxide, which causes a vascular imbalance towards 
vasoconstriction16.
It is also known that., in physiological conditions, 
the myocardium metabolizes, preferably, free fatty 
acids; however, in ischemic conditions, it uses glu-
cose in a relatively higher proportion. Nevertheless, 
the insulin resistance developed during the AMI 
acute stage generates an immediate limiting factor 
to the absorption of the energy substrate, which can 
contribute to the worsening of the myocardium in-
jury. Thus, both endothelial dysfunction caused by 
hyperglycemia and insulin resistance can explain the 
adverse outcomes of exacerbated hyperglycemia in 
the second acute stage of AMI1,11.





























Average reduction of blood glucose in the intensive treatment group in comparison  
with the average estimated blood glucose
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would be the ideal blood glucose target after the AMI, 
since, for the reasons previously mentioned, even pa-
tients who did not have diabetes were hyperglycemic 
upon the admission of the ischemic event. Thus, was 
born the 1995 Digami3 study, which set out to study 
620 patients grouped into a more permissive hyper-
glycemic approach and a more intensive approach 
for the control of blood glucose levels through the 
use of a glucose-insulin solution. They were, initial-
ly, encouraging of an intensive strategy, since after a 
40.8 months follow-up there was a reduction of 11% 
of mortality in the intensive group, which was more 
evident in the low-risk groups who were not previ-
ously treated with insulin therapy. 
The following studies then – Digami-24 e HI-55 
– tried to reproduce a similar design to the Digami 
but were not very successful. In the first one, there 
was no difference in mortality between the groups, 
possibly due to the excellent blood glucose levels on 
both. In the HI-5, the absence of significant differ-
ences in mortality could be explained by the reduced 
number of patients in a study that, perhaps, was not 
adequately blinded.  
When we analyze the results of these three stud-
ies (Digami, Digami-2 e HI-5), we can see that the 
post-intensive treatment blood glucose level was of 
172.8 mg/dl, 163.8 mg/dl, and 144 mg/dl, respective-
ly, while in the groups randomized for the conser-
vative treatment it was 210.6 mg/dl, 180 mg/dl, and 
145.8 mg/dl; the average for HbA1c was 8.1%, 7.23%, 
and 7%, also respectively. The Digami data show that 
this study had the highest values for blood glucose in 
both groups in comparison with the other two stud-
ies, while the HI-5 was the one with the lowest val-
ues. This analysis suggests that higher blood glucose 
values might be related to better outcomes when 
compared with lower values in more intensive ap-
proaches. Accordingly, the meta-regression results 
suggested there is a tenuous line between effective-
ness and safety for the reduction of blood glucose in 
the acute stage.
The studies on GIK therapy were motivated by 
the theoretical benefits of the solution in increasing 
the availability of glucose and potassium to the myo-
cardium associated with the insulin effect that facili-
tates the glucose oxidation, reduces circulating fatty 
acids, thus improving the parameters for coagulation 
and the anti-inflammatory effects, and reducing ar-
rhythmias and changes in contractility. The studies 
included in this meta-analysis assessed 13,031 pa-
tients who underwent GIK therapy and 13,007 who 
underwent the conventional treatment; Create-Ecla10 
had the largest sample, with 20,201 patients. 
The Gips-I8 study compared the GIK therapy in-
fusion or placebo in 940 AMI patients eligible for 
primary angioplasty in 8-12 hours, showing clinical 
benefits for the patients, with no signs of heart fail-
ure; however, the following study, Gips-II9, could not 
confirm this finding. 
Similarly, in the most recent Create-Ecla, a study 
that assessed the effects of a high dose of GIK did 
not present a significant difference in mortality. The 
Oasis-617 study was prematurely interrupted after 
2,748 patients were enrolled after the publication of 
the Create-Ecla; the Oasis-6 showed no benefits to 
the GIK treatment. 
Despite that, a recent analysis of the Oasis-6 and 
Create-Ecla studies combined the populations of 
both, showing an increase in mortality for the treat-
ment with GIK, especially over the first three days.
In a meta-analysis published in 1997 by Fath-Or-
doubadi & Beatt18 and reviewed by Mamas et al.19 in 
2010, it was demonstrated that the GIK therapy in 
the studies analyzed conducted during a pre-revas-
cularization/fibrinolysis period presented benefits 
for the clinical outcome. Upon comparing these data 
with more recent studies, it is possible that the GIK 
therapy benefits only patients in whom the reperfu-
sion has not been reached.
When analyzing the studies, it is evident that the 
interventions by the GIK studies, overall, provid-
ed better blood glucose control for patients in both 
groups. For those submitted to GIK therapy, there 
was a discrete increase in blood glucose in compari-
son with the placebo group, whose average pre-ran-
domization blood glucose was of 150.48. After the 
intervention, the blood glucose average in the treat-
ment group was of 137.7, and the average in the pla-
cebo group was 131.4. Both results were very similar, 
which might justify the absence of benefits for the 
reduction of mortality when both groups were com-
pared.
CONCLUSION
Few reported studies assess blood glucose con-
trol guided by goals in an intensive environment and 
that included acute coronary syndrome patients. The 
present meta-analysis demonstrated that the data 
on the interval between blood glucose levels that 
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should be sought during the acute stage of the AMI 
is inconsistent and that GIK therapy did not present 
any benefits for this same group of patients. On the 
other hand, our study supports the hypothesis that 
there must be a fine limit between effectiveness and 
safety for blood glucose reduction in the acute stage. 
Thus, the reasonable blood glucose targets should be 
guided, preferably, by the average estimated blood 
glucose and should not exceed a reduction of 36 mg/
dL of blood glucose. Additional studies are still neces-
sary to confirm the ideal targets and dissect the dif-
ferences between diabetic and non-diabetic patients.
RESUMO
INTRODUÇÃO: No infarto agudo do miocárdio (IAM), cada incremento de 18 mg/dl (1 mmol/L) se associa a um aumento de 3% na 
mortalidade. As estratégias de redução da glicemia tentadas até o momento, entretanto, não trouxeram resultados animadores.
METODOLOGIA: Foram pesquisadas nas bases de dados Medline (PubMed) e Cochrane Library os ensaios clínicos randomizados (ECRs) 
de 1995 a 2017 que utilizaram estratégia intensiva ou a terapia GIK no controle glicêmico durante a fase aguda do IAM. Foram incluídos 
oito estudos. Para identificar os efeitos da insulinoterapia ou da terapia GIK, calculamos um risco relativo geral (RR) com meta-análises 
de modelos de efeitos fixos e aleatórios. Um valor de p-bicaudal < 0,05 foi considerado estatisticamente significativo.
RESULTADOS: Foram incluídos 28.151 pacientes, sendo 1.379 no grupo de tratamento intensivo da glicemia, 13.031 no GIK e 13.741 no 
controle. A mortalidade total foi de 2.961 (10,5%), computando um risco relativo de 1,03 [95%CI 0,96–1,10]; I2 = 31%; p = 0,41 para o 
grupo intensivo ou GIK contra o grupo conservador. Reduções intensas (> 36 mg/dL) em relação à glicemia estimada média se asso-
ciaram à maior mortalidade, enquanto reduções menores não se associaram com seu incremento ou redução. A redução glicêmica na 
fase aguda em relação à glicemia estimada média foi mais efetiva e segura na faixa em torno de 18 mg/dL.
CONCLUSÃO: Esta meta-análise levanta a hipótese de haver um limite tênue entre efetividade e segurança para a redução glicêmica na 
fase aguda, sendo que os alvos não devem exceder uma redução maior do que 36 mg/dL de glicemia. 
PALAVRAS-CHAVE: Hiperglicemia. Infarto do miocárdio. Meta-análise como assunto. Efetividade. Segurança. Cuidados críticos.
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ANNEX 1
Data Source and Research
The following terms were used in our search: 
“acute myocardial infarction”, “diabetes mellitus” 
and “stress hyperglycemia” and “stress hyperglyce-
mia in acute myocardial infarction” and (ensaio clíni-
co aleatório controlado OU ensaio clínico controlado 
OU randomizado OU placebo OU terapia medica-
mentosa OU aleatoriamente OU julgamento ou gru-
pos NÃO animais) and (ensaio clínico randomizado 
controlado e humanos) and (ensaio clínico controla-
do aleatório e humanos).
During the search strategy, we selected the follow-
ing languages: English, Spanish, and Portuguese. How-
ever, all relevant articles were published in English, con-
ducted in human beings, and classified as RCTs.
– Definitions
 Hyperglycemia in an acute myocardial infarc-
tion event was characterized according to the defi-
nition of each researcher. Usually, these definitions 
included the following terms from the MedDRA ter-
minology: “hyperglycemia after acute myocardial in-
farction” and “hyperglycemia and mortality in acute 
myocardial infarction.”
– Data Extraction and Quality Assessment
Two researchers who were not involved in any of 
the studies selected collected the data using a pre-set 
table and assessed, independently, the precision of 
the data, solving any discrepancies through consen-
sus after a discussion with a third researcher. The 
following items were extracted from the studies in-
cluded: name of the first author, year of publication, 
study design, characteristics of the patients, sample 
size, duration of the intervention, type of dose con-
trol, clinical outcomes, and adverse events. If a study 
was published more than once, we included the most 
recent report. If the patients were recruited for more 
than one study, they were not counted twice. The Co-
chrane Collaboration¹ tool to assess the risk of bias 
was used to assess the different types of bias within 
the studies included in our meta-analysis, and the 
quality of the study was assessed using the Grade² 
system. Two unblinded researchers independently 
assessed the potential risk of bias in the RCTs using 
the methods described in the Cochrane Collaboration 
guidelines. Our co-primary outcomes were: 1) Blood 
glucose levels after one of the approaches had been 
applied, and 2) mortality for each of the approaches. 
– Studies Included and Excluded
Using the Medline/PubMed, Cochrane Library 
and ClinicalTrials.gov databases, we identified 36 
citations that used the search terms previously de-
fined. After implementing our inclusion/exclusion 
criteria, we excluded 25 studies that did not present 
data on mortality or a comparison between a more 
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glycemia and more conservative approaches, or that 
presented randomization or data analysis (n=2) bias-
es, or were previous meta-analysis, which then re-
sulted in 11 studies considered relevant for this me-
ta-analysis.
Data Handling and Analysis
Dichotomous variables are reported as percent-
ages, while continuous variables are reported as 
average ± SD or median (interquartile range). The 
baseline data were obtained through weighted calcu-
lation. To identify the potential effects of the inten-
sive strategy for blood glucose control, we calculated 
an overall risk ratio (RR) with meta-analyses of fixed 
and random effects models. Probability indexes and 
risk ratios were universally identical during the data 
analysis. We assessed the statistical heterogeneity 
between the trials using I2 statistics (with 95% CI)³, 
which provides a measure of the proportion of over-
all variation that can be attributed to heterogeneity 
between trials. We used risk ratios obtained through 
a fixed and random effects meta-analysis because 
they can be used as a sensitivity analysis. We used 
meta-regression analyses to investigate the possible 
sources of heterogeneity among the trials. 
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